Evidence map›Paper›PMID 38591096›Full record

ArticleEuropean urology open science2024

Intraoperative Performance of DaVinci Versus Hugo RAS During Radical Prostatectomy: Focus on Timing, Malfunctioning, Complications, and User Satisfaction in 100 Consecutive Cases (the COMPAR-P Trial).

Alessandro Antonelli, Alessandro Veccia, Sarah Malandra, Riccardo Rizzetto, Vincenzo De Marco, Alberto Baielli, Andrea Franceschini, Francesca Fumanelli, Francesca Montanaro, Iolanda Palumbo and 5 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in European urology open science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05766163 (Comparative Evaluation of New Surgical Robotic Platforms for the Radical Prostatectomy Procedure), which is not on this map. Cited by 25 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 8 pooled it
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05766163 naunknown statusnot on this map

Comparative Evaluation of New Surgical Robotic Platforms for the Radical Prostatectomy Procedure

TypeinterventionalSponsorAzienda Ospedaliera Universitaria Integrata VeronaRan2023 to 2024Enrolled150ConditionsProstate CancerArmsDaVinci RARP, Hugo RARP, Versius RARP
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 8 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Hugo™ RAS versus da VinciBMC surgery · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Medtronic's HugoJournal of robotic surgery · 2024
    Pooled it
  9. Article
  10. Da VinciSurgical endoscopy · 2026
    Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Optimizing arm placement in the HugoUpdates in surgery · 2025
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Alessandro AntonelliDepartment of Surgery, Dentistry, Pediatrics and Gynecology, Urology Unit, University of Verona - Azienda Ospedaliera Universitaria Integrata Verona (AOUI) - Verona, Italy.
Alessandro VecciaDepartment of Surgery, Dentistry, Pediatrics and Gynecology, Urology Unit, University of Verona - Azienda Ospedaliera Universitaria Integrata Verona (AOUI) - Verona, Italy.
Sarah MalandraDepartment of Surgery, Dentistry, Pediatrics and Gynecology, Urology Unit, University of Verona - Azienda Ospedaliera Universitaria Integrata Verona (AOUI) - Verona, Italy.
Riccardo RizzettoDepartment of Surgery, Dentistry, Pediatrics and Gynecology, Urology Unit, University of Verona - Azienda Ospedaliera Universitaria Integrata Verona (AOUI) - Verona, Italy.
Vincenzo De MarcoDepartment of Surgery, Dentistry, Pediatrics and Gynecology, Urology Unit, University of Verona - Azienda Ospedaliera Universitaria Integrata Verona (AOUI) - Verona, Italy.
Alberto BaielliDepartment of Surgery, Dentistry, Pediatrics and Gynecology, Urology Unit, University of Verona - Azienda Ospedaliera Universitaria Integrata Verona (AOUI) - Verona, Italy.
Andrea FranceschiniDepartment of Surgery, Dentistry, Pediatrics and Gynecology, Urology Unit, University of Verona - Azienda Ospedaliera Universitaria Integrata Verona (AOUI) - Verona, Italy.
Francesca FumanelliDepartment of Surgery, Dentistry, Pediatrics and Gynecology, Urology Unit, University of Verona - Azienda Ospedaliera Universitaria Integrata Verona (AOUI) - Verona, Italy.
Francesca MontanaroDepartment of Surgery, Dentistry, Pediatrics and Gynecology, Urology Unit, University of Verona - Azienda Ospedaliera Universitaria Integrata Verona (AOUI) - Verona, Italy.
Iolanda PalumboDepartment of Surgery, Dentistry, Pediatrics and Gynecology, Urology Unit, University of Verona - Azienda Ospedaliera Universitaria Integrata Verona (AOUI) - Verona, Italy.
Greta PettenuzzoDepartment of Surgery, Dentistry, Pediatrics and Gynecology, Urology Unit, University of Verona - Azienda Ospedaliera Universitaria Integrata Verona (AOUI) - Verona, Italy.
Luca RoggeroDepartment of Surgery, Dentistry, Pediatrics and Gynecology, Urology Unit, University of Verona - Azienda Ospedaliera Universitaria Integrata Verona (AOUI) - Verona, Italy.
Maria Angela CerrutoDepartment of Surgery, Dentistry, Pediatrics and Gynecology, Urology Unit, University of Verona - Azienda Ospedaliera Universitaria Integrata Verona (AOUI) - Verona, Italy.
Riccardo BertoloDepartment of Surgery, Dentistry, Pediatrics and Gynecology, Urology Unit, University of Verona - Azienda Ospedaliera Universitaria Integrata Verona (AOUI) - Verona, Italy.
Collaborators
University of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective: The Hugo RAS and DaVinci Xi systems are used for performing robot-assisted radical prostatectomy (RARP). This study aims to compare these two platforms providing granular and comprehensive data on their intraoperative performance. Methods: The Comparison of Outcomes of Multiple Platforms for Assisted Robotic surgery-Prostate (COMPAR-P) trial is a prospective post-market study (clinicaltrials.org NCT05766163). Enrollment began in March 2023, allocating patients to DaVinci or Hugo RAS for RARP, without selection criteria, for up to 50 consecutive cases. Two experienced console surgeons performed the procedures, following the same technique. Evaluation focused on timing, learning curves, malfunctioning events, complications, and users' satisfaction, using standard statistical methods, including the cumulative summation analysis (CUSUM) for the learning curve assessment. Key findings and limitations: Fifty patients each were enrolled for DaVinci (DV-RARP) and Hugo RAS (H-RARP) RARP. Baseline features were balanced. DV-RARP showed significantly shorter "setup" and "console" phase durations than H-RARP (37 vs 55 min and 97 vs 126 min, respectively, Conclusions and clinical implications: This prospective study compared unselected patients who underwent DV-RARP and H-RARP. More malfunctioning events occurred in case of Hugo RAS, but surgical outcomes were similar. Longer operative times for Hugo RAS were attributed to meticulous care with the novel platform. Improvement potential was evident within a few procedures, providing valuable insights for adopting this new platform. Patient summary: This study compared two advanced robotic systems, DaVinci and Hugo RAS, used to remove the prostate in patients diagnosed with prostate cancer. While both systems showed similar surgical outcomes, the newer Hugo RAS system required more meticulous movements, leading to slightly longer operation times. The findings suggest that, with further experience, both systems can provide effective treatment options for patients undergoing prostate surgery.

Indexed as

DaVinciHugo RASPerformanceRadical prostatectomyRobotic surgerySurgical outcomes

Identifiers

PMID38591096
PMCPMC11000201
OpenAlexW4394760452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.